Grifols has reported to the press the positive result of the AMBAR trial in patients with Alzheimer’s disease in a moderate phase. Our unit (located in the General University Hospital of Catalonia) participated in this phase II clinical trial. Patients were treated with several plasmapheresis and albumin replacement, with or without immunoglobulins administration, compared to…

Compartir:

Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in mild Alzheimer, which was positive. We have started the open label extension for the patients who participated in this phase II study. We also started the development of the phase III clinical trial with this antiamyloid monoclonal antibody of EISAI…

Compartir:

We have initiated a clinical trial to assess the efficacy and safety of a drug that inhibits the proteases of a bacterium (P.gingivalis) that is detected in the brains of Alzheimer’s patients. It is a new approach to this pathology, absolutely different from the rest of ongoing projects. More information at www.gaintrial.com.

Compartir:

We started a phase II / III trial with an inhibitor of TAU protein aggregation (LMTM, TRx0237), administered orally, in patients with early-stage Alzheimer’s disease. It involves a change in the therapeutic target hitherto chosen: the amyloid protein

Compartir:

Our Unit participated in a Phase II clinical trial, with a monoclonal anti-amyloid in Alzheimer’s, which was positive. We have been selected to develop the phase III trial with this Eisai drug.  

Compartir:

Our Unit has surpassed two centers from the United States in the randomization of patients included in a clinical trial with a neuromodulator. In addition, the sum of our activity in Sant Cugat and in Manresa has reached more than 73% of the all patients included in Spain.

Compartir:

No dude en llamarnos        1-+34 935 656 000